Bold Therapeutics Inc.
Ashish Kumar is a Senior Scientist at Bold Therapeutics Inc., specializing in the transition of oncology projects from preclinical and translational stages to clinical trials, while enhancing therapeutic strategies. Previously, as a Postdoctoral Research Fellow at The University of British Columbia, Ashish developed multiple projects focused on Ewing Sarcoma, identifying molecular targets for treatment resistance and metastasis. At the University of Helsinki, Ashish utilized advanced techniques to investigate cellular interactions related to aging and gastrointestinal cancer. Ashish's academic foundation includes a Ph.D. in Molecular and Cellular Biology of Cancer from the National Institute of Immunology, where research focused on cancer cell stress responses, alongside a Master of Science in Life Sciences and a Bachelor’s in Biotechnology from recognized institutions in India.
Bold Therapeutics Inc.
Bold Therapeutics is a clinical stage biotechnology company developing a first-in-class cancer therapy for the treatment of gastric, pancreatic, colorectal and other cancers in combination with existing anti-cancer therapies.